Skip to main content

Table 3 Analyses of the associations of sCD73 activity and progression-free survival

From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

  Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Gender (M vs. F) 1.64 (0.73–3.70) P = 0.23 n.s.
Age, years (≥ 62 vs. < 62) 1.30 (0.59–2.89) P = 0.52 n.s.
BRAF status (mut vs. wt) 0.72 (0.30–1.69) P = 0.45 n.s.
LDH, IU/L (≥ 480 vs. < 480) 2.37 (1.04–5.39) P = 0.04 n.s.
Line of treatment (> 2 vs. 2) 2.34 (1.02–5.34) P = 0.04 n.s.
Brain METS (yes vs. no) 1.33 (0.53–3.36) P = 0.54 n.s.
Basal sCD73 activity (≥ 27.8 vs. < 27.8) 4.24 (1.64–10.93) P = 0.003 4.24 (1.64–10.93) P = 0.003
  1. HR hazard ratio, CI confidence interval, n.s. not significant, M male, F female, MUT mutant, WT wild-type, LDH lactate dehydrogenase, IU/L International Units per Liter, METS metastasis, sCD73 soluble CD73
  2. P values are from Cox proportional hazard Regression models